Common use of Additional Surviving Provisions Clause in Contracts

Additional Surviving Provisions. In addition and without prejudice to the provisions of Section 14.6 (General Effects of Expiration or Termination), in the event of any expiration or termination of this Agreement (whether as a whole or with respect to a particular Product) the following provisions shall survive: Article I (Definitions), VII (Financial Consideration) (with respect to amounts incurred or earned prior to any such expiration or termination), VIII (Payments) (with respect to amounts incurred or earned prior to any such expiration or termination), XI (Confidentiality, Publications and Press Releases), XIII (Indemnification and Insurance), XIV (Term and Termination) and XV (Miscellaneous) and Sections 2.9.2 (Non-Collaboration Territory Agreements), 3.1.5 (Ownership of Development and Safety Data) (subject to Section 14.6.2), 5.7.2 (Records; Audit Right) (with respect to amounts incurred or earned prior to any such expiration or termination), 10.1 (Program Intellectual Property Ownership), 10.2 (Copyright Ownership), 10.3 (Product Trademarks), 10.4 (Joint Ownership), 10.6 (License Grant by BeiGene), Section 12.5 (Privacy and Data Protection), 12.7 (Disclaimer of Warranties) and 12.8 (Limitation of Liability).

Additional Surviving Provisions. In addition and without prejudice to the provisions of Section 14.6 15.4 (General Effects Effect of Expiration or Termination), in the event of any expiration or termination of this Agreement (whether as a whole or with respect to a particular Product) the following provisions shall survive: Article I (Definitions), VII Article VIII (Financial Consideration) (with respect to amounts incurred or earned prior to any such expiration or termination), VIII Article IX (Payments) (with respect to amounts incurred or earned prior to any such expiration or termination and any audit rights set forth in Section 9.4), Article XI (Intellectual Property)(solely with respect to ownership of intellectual property and any enforcement, infringement or defense action initiated in good faith prior to such expiration or termination), XI Article XII (Confidentiality, Publications and Press Releases), XIII Article XIV (Indemnification and Insurance), XIV (Term and Termination) and XV Article XVI (Miscellaneous) and Sections 2.9.2 Section 4.8 (Non-Collaboration Territory Agreements), 3.1.5 (Ownership of Development and Safety Data) (subject to Section 14.6.2), 5.7.2 (Records; Audit Right) (with respect to amounts incurred or earned prior to any such expiration or termination), 10.1 (Program Intellectual Property Ownership), 10.2 (Copyright Ownership), 10.3 (Product Trademarks), 10.4 (Joint Ownership), 10.6 (License Grant by BeiGenePharmacovigilance Agreement), Section 12.5 4.10 (Sharing of Data and Know-How; Rights of Reference), Section 13.4 (Privacy and Data Protection), 12.7 Section 13.6 (Disclaimer of Warranties) and 12.8 ), Section 13.7 (Limitation of Liability)) and Section 15.4 (Effects of Termination) and this Section 15.5.